Alto Neuroscience, Inc.
ANRO · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.05 | 0.00 | 0.19 |
| FCF Yield | -9.10% | -23.14% | -28.38% | -11.85% |
| EV / EBITDA | 0.10 | 3.58 | 5.27 | 2.53 |
| Quality | ||||
| ROIC | -10.75% | -12.40% | -9.47% | -10.09% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.70 | 0.78 | 1.09 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 28.02% | 16.89% | -22.57% | -6.25% |
| Safety | ||||
| Net Debt / EBITDA | 8.25 | 7.09 | 9.33 | 10.29 |
| Interest Coverage | -23.00 | -28.92 | -26.21 | -51.04 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,129.94 | -1,503.90 | 0.00 | -835.94 |